Q

Quotient Sciences | Nottingham

Research site

(Unclaimed)

Location

Mere Way Ruddington Fields, Nottingham, Nottingham, England

Site insights

Top conditions

Top treatments

anle138b

BOS172767

FDL169

Relugolix

BMS-986165

NM-101

DNDI-0690

GLPG3970

Trimethoprim

14C-NW-3509

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 58 total trials

A First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

This is a single center, double-blind, randomized, placebo-controlled, single ascending subcutaneous dose study in lean to overweight or obese but ot...

Enrolling

Overweight

Healthy Volunteers

Drug: GUB014295-PLACEBO

Drug: GUB014295

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral...

Active, not recruiting

Healthy

Drug: BI 1015550

Drug: Moxifloxacin

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in health...

Enrolling

Healthy Volunteers

Drug: Afimetoran

Drug: Famotidine

First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subject...

Enrolling

Male Contraception

Drug: YCT-529

Drug: YCT-529 Placebo

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and multiple-ascending dose (Part 2) study of NM-101 in healthy...

Not yet enrolling

Parkinson Disease

Drug: NM-101

Drug: Placebo